'	( )				s	heet <u>-1</u>	of	1			
FORM PTO-14 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT					ATTY. DOCKE	APPLICATION NO.: 10/791,910					
INFO	DRM	ATION DISCLOS BY APPLIC		ATEMENT	APPLICANT: Duane A. Bu	rnett, et a	ıl.				
	(Use several sheets if necessary)				FILING DATE: 03/07/2003		GROUP: To Be Assigned				
			U.S. P.	ATENT DOCUM	MENTS						
*EXAMINER INITIAL	EXAMINER DOCUMENT DATE		NAN	NAME			FILING DATE IF APPROPRIATE				
	AA AB			-				-			
	AC		l								
	AD										
	AE	\	<del> </del>			<u> </u>	ļ	<b></b>			
	AF	<u></u>	<u> </u>	ļ		<del> </del>	<u> </u>	<del> </del>			
	AG AH		<del> </del>	1	<del></del>	-		╁──			
	AI		<del>                                     </del>	<del> </del>		<del> </del>	<del> </del> -	┼──	-		
	ĀĴ		<u> </u>			<del></del>		<u> </u>			
	AK		<u> </u>		<del>-</del>						
		·	FOREIGN	PATENT DOC	UMENTS		*				
		DOCUMENT	DATE	COUNTRY		CLASS	SUB-	TRANS	ANSLATION		
		NUMBER	<u> </u>				CLASS	YES	NO		
	AL					<u> </u>		<u> </u>			
	AM					ļ		<u> </u>	<u> </u>		
	AN		ļ				ļ	<del> </del>	<del> </del>		
ļ	AO AP		<del> </del>	<u> </u>			-	<del> </del>	<del> </del>		
		HER DOCUMENT	TS (Includ	ling Author Titl	o Data Par	tinent Pa	egos Et	<u> </u>	<u> </u>		
	AQ								luction		
MB	ΛQ	T. Kosoglou et al., "CoAdministration of Simvastatin and Ezetimibe Leads to Significant Reduction in LDL-Cholesterol", Proceedings of 3 <sup>rd</sup> International Congress on Coronary, Artery Disease from Prevention to Intervention, Lyon, France p. 271 (2000), XP008027568									
	AR										
	AS										
	AT										
	ΔΠ			•							

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

01/26/2007

/Mark L. Berch/

**EXAMINER** 



Please type a plus sign (+) inside this box 

Approved for use through 10/31/2001. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known			
INFORM	NOITAI	I DISCLO	SURE	Application Number	10/791,910		
STATEMENT BY APPLICANT			CANT	Filing Date	March 3, 2004		
(use as many shorts as necessary)				First Named Inventor	Duane Burnett et al.		
				Group Art Unit	1624		
				Examiner Name	Mark L. Berch		
Sheet	#	of	1	Attorney Docket Number	CV06025US/4686-050111		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cite and/or country where published.	T²				
WB	.3	Luis Gruberg, MD, "Inflammatory Markers in Acute Coronary Syndromes: C-reactive Protein (CRP) and Chlamydia," American Heart Association Scientific Sessions 2000.					
<u></u>							
	,						
Examiner Signature	<u> </u>	Man Bow Date Considered 4/1/06					

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>3</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>3</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.